XML 19 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating activities    
Net loss $ (75,729) $ (96,084)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 949 767
Stock-based compensation expense 12,282 12,879
Inventory write-offs, net 3,241  
Non-cash accretion of discount on marketable securities (1,339)  
Non-cash interest expense from amortization of debt discount & issuance costs 656 3,696
Option payment to Shanghai Junshi Biosciences Ltd. ("Junshi Biosciences")   35,000
Loss on debt extinguishment   6,222
Other non-cash adjustments, net 554 592
Changes in operating assets and liabilities:    
Trade receivables, net 8,529 5,991
Inventory (2,671) (2,962)
Prepaid manufacturing 1,861 248
Other prepaid, current and non-current assets 2,057 (7,632)
Accounts payable 11,739 4,757
Accrued rebates, fees and reserves 1,236 (7,133)
Accrued compensation (10,188) (7,144)
Accrued and other current and non-current liabilities (21,909) (3,242)
Net cash used in operating activities (68,732) (54,045)
Investing activities    
Purchases of property and equipment (152) (615)
Proceeds from disposal of property and equipment 178  
Proceeds from maturities of investments in marketable securities 17,500  
Option payment to Junshi Biosciences   (35,000)
Net cash provided by (used in) investing activities 17,526 (35,615)
Financing activities    
Proceeds from 2027 Term Loans, net of debt discount & issuance costs   191,190
Proceeds from issuance of common stock under ATM Offering, net of issuance costs 6,835  
Proceeds from issuance of common stock upon exercise of stock options 103 544
Taxes paid related to net share settlement of RSUs (2,781) (2,658)
Repayment of 2022 Convertible Notes and premiums   (109,000)
Repayment of 2025 Term Loan, premiums and exit fees   (81,750)
Other financing activities (353) (181)
Net cash provided by (used in) financing activities 3,804 (1,855)
Net decrease in cash, cash equivalents and restricted cash (47,402) (91,515)
Cash, cash equivalents and restricted cash at beginning of period 63,987 417,635
Cash, cash equivalents and restricted cash at end of period $ 16,585 $ 326,120